Shenyang Xingqi Pharmaceutical Hits Day High with 3.18% Surge

Shenyang Xingqi Pharmaceutical Co., Ltd. has experienced a notable increase of 3.18% on March 4, 2026, reaching an intraday high of CNY 71.38. This performance stands in contrast to the broader market, as the China Shanghai Composite index declined by 1.26% on the same day. Over the past year, Shenyang Xingqi has demonstrated impressive growth, with a remarkable 41.71% increase in stock value, significantly outperforming the Shanghai Composite's 22.49% gain. The company's strong financial metrics include a net profit growth of 40.39% and a return on equity (ROE) of 28.64%. Additionally, the operating cash flow reached a record high of CNY 524.17 million, while net sales for the quarter grew by 52.83%, totaling CNY 528.5 million. With a market capitalization of CNY 13,037 million, Shenyang Xingqi operates within the pharmaceuticals and biotechnology sector, showcasing a robust price-to-earnings (P/E) ratio of 32.00 and a price-to-book value of 7.02. The company also offers a dividend yield of 2.04%, reflecting its commitment to returning value to shareholders.